Lonza to establish multi-product fill and finish line in China

Lonza's Guangzhou facility

The new production line at Guangzhou site will supply global and domestic companies with clinical and commercial batches

The new investment will see the company install an aseptic drug product fill and finish production line at the 17,000-m2 cGMP mammalian facility, which only began operations in Q2 this year.

Lonza has said the new production line, which is expected to deliver its first cGMP batch later this year, will significantly expand the site's capabilities, supporting global and domestic customers with supply for clinical trials and commercial batches in China.

In line with the company's strategy to provide integrated end-to-end solutions, the introduction of drug product manufacturing at Guangzhou will provide a combined drug substance and drug product manufacturing service offering.

The sterile, multi-product fill and finish line will support liquid and lyophilized products. The installation is expected to be completed in 2022 and will create more than 150 new positions.

To facilitate the expansion in China, Lonza also plans to expand the footprint of its global Drug Product Services hub in Basel (Switzerland), which supports drug product capabilities across the company's global network by providing formulation development and process development.